Sandro Sorbi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2576876/publications.pdf

Version: 2024-02-01

351 papers	28,320 citations	12330 69 h-index	7518 151 g-index
363 all docs	363 docs citations	363 times ranked	29054 citing authors

#	Article	IF	Citations
1	Comparison of clinical rating scales in genetic frontotemporal dementia within the GENFI cohort. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 158-168.	1.9	7
2	Practice effects in genetic frontotemporal dementia and at-risk individuals: a GENFI study. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 336-339.	1.9	1
3	Common Genetic Variation and Age of Onset of Anorexia Nervosa. Biological Psychiatry Global Open Science, 2022, 2, 368-378.	2.2	10
4	Gender differences in cognitive reserve: implication for subjective cognitive decline in women. Neurological Sciences, 2022, 43, 2499-2508.	1.9	12
5	Effect of BDNF Val66Met polymorphism on hippocampal subfields in multiple sclerosis patients. Molecular Psychiatry, 2022, 27, 1010-1019.	7.9	10
6	A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. Brain, 2022, 145, 1805-1817.	7.6	27
7	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum <scp>NfL</scp> and <scp>pNfH</scp>: A Longitudinal Multicentre Study. Annals of Neurology, 2022, 91, 33-47.	5.3	21
8	An Automated Toolbox to Predict Single Subject Atrophy in Presymptomatic Granulin Mutation Carriers. Journal of Alzheimer's Disease, 2022, , 1-14.	2.6	3
9	Examining empathy deficits across familial forms of frontotemporal dementia within the GENFI cohort. Cortex, 2022, 150, 12-28.	2.4	2
10	Dataâ€driven staging of genetic frontotemporal dementia using multiâ€modal <scp>MRI</scp>. Human Brain Mapping, 2022, 43, 1821-1835.	3.6	7
11	Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. Alzheimer's and Dementia, 2022, 18, 1408-1423.	0.8	24
12	Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia. Neurobiology of Aging, 2022, , .	3.1	1
13	Huntingtin gene intermediate alleles influence the progression from subjective cognitive decline to mild cognitive impairment: A 14â€year followâ€up study. European Journal of Neurology, 2022, 29, 1600-1609.	3.3	4
14	CAG Repeats Within the Non-pathological Range in the HTT Gene Influence Personality Traits in Patients With Subjective Cognitive Decline: A 13-Year Follow-Up Study. Frontiers in Psychiatry, 2022, 13, 826135.	2.6	2
15	Anomia is present pre-symptomatically in frontotemporal dementia due to MAPT mutations. Journal of Neurology, 2022, 269, 4322-4332.	3.6	1
16	The <scp>CBIâ€R</scp> detects early behavioural impairment in genetic frontotemporal dementia. Annals of Clinical and Translational Neurology, 2022, 9, 644-658.	3.7	1
17	Plasma neurofilament light chain as a biomarker of Alzheimerâ€™s disease in Subjective Cognitive Decline and Mild Cognitive Impairment. Journal of Neurology, 2022, 269, 4270-4280.	3.6	30
18	New insights into the genetic etiology of Alzheimerâ€™s disease and related dementias. Nature Genetics, 2022, 54, 412-436.	21.4	700

#	Article	IF	Citations
19	Association of rs3027178 polymorphism in the circadian clock gene PER1 with susceptibility to Alzheimerâ€™s disease and longevity in an Italian population. GeroScience, 2022, 44, 881-896.	4.6	6
20	Unravelling neural correlates of empathy deficits in Subjective Cognitive Decline, Mild Cognitive Impairment and Alzheimerâ€™s Disease. Behavioural Brain Research, 2022, 428, 113893.	2.2	6
21	Intermediate alleles of HTT: A new pathway in longevity. Journal of the Neurological Sciences, 2022, 438, 120274.	0.6	3
22	Loss of speech and functional impairment in Alzheimer's disease-related primary progressive aphasia: predictive factors of decline. Neurobiology of Aging, 2022, 117, 59-70.	3.1	6
23	Brain metabolic connectivity reconfiguration in the semantic variant of primary progressive aphasia. Cortex, 2022, , .	2.4	3
24	Shared genetic risk between eating disorderâ€•and substanceâ€•useâ€•related phenotypes: Evidence from genomeâ€•wide association studies. Addiction Biology, 2021, 26, e12880.	2.6	28
25	Genetic variation in APOE, GRN, and TP53 are phenotype modifiers in frontotemporal dementia. Neurobiology of Aging, 2021, 99, 99.e15-99.e22.	3.1	8
26	Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia. Alzheimer's and Dementia, 2021, 17, 500-514.	0.8	36
27	Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes. Alzheimer's and Dementia, 2021, 17, 969-983.	0.8	31
28	Impairment of episodic memory in genetic frontotemporal dementia: A GENFI study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12185.	2.4	11
29	Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia. JAMA Network Open, 2021, 4, e2030194.	5.9	42
30	MRI data-driven algorithm for the diagnosis of behavioural variant frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 608-616.	1.9	10
31	Late-onset Huntington disease: An Italian cohort. Journal of Clinical Neuroscience, 2021, 86, 58-63.	1.5	3
32	Polyneuropathy and monoclonal gammopathy of undetermined significance (MGUS); update of a clinical experience. Journal of the Neurological Sciences, 2021, 423, 117335.	0.6	4
33	Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. Neurology, 2021, 96, e2296-e2312.	1.1	52
34	Behavioural disorders in <scp>A</scp>lzheimer's disease: the descriptive and predictive role of brain <scp>¹⁸F</scp>â€fluorodesoxyglucoseâ€positron emission tomography. Psychogeriatrics, 2021, 21, 514-520.	1.2	1
35	Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. Biological Psychiatry, 2021, 89, 825-835.	1.3	10
36	Dual Effect of PER2 C111G Polymorphism on Cognitive Functions across Progression from Subjective Cognitive Decline to Mild Cognitive Impairment. Diagnostics, 2021, 11, 718.	2.6	3

#	Article	IF	Citations
37	Whole-genome sequencing analysis of semi-supercentenarians. ELife, 2021, 10, .	6.0	37
38	Characterizing the Clinical Features and Atrophy Patterns of MAPT -Related Frontotemporal Dementia With Disease Progression Modeling. Neurology, 2021, 97, e941-e952.	1.1	29
39	Common variants in Alzheimerâ€™s disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	12.8	140
40	The Effect of CAG Repeats within the Non-Pathological Range in the HTT Gene on Cognitive Functions in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment. Diagnostics, 2021, 11, 1051.	2.6	7
41	The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort. Alzheimer's Research and Therapy, 2021, 13, 127.	6.2	12
42	The complexity of Alzheimerâ€™s disease: an evolving puzzle. Physiological Reviews, 2021, 101, 1047-1081.	28.8	110
43	Neurofilament Light Chain and Intermediate HTT Alleles as Combined Biomarkers in Italian ALS Patients. Frontiers in Neuroscience, 2021, 15, 695049.	2.8	1
44	Dissemination in time and space in presymptomatic granulin mutation carriers: a GENFI spatial chronnectome study. Neurobiology of Aging, 2021, 108, 155-167.	3.1	3
45	Differential early subcortical involvement in genetic FTD within the GENFI cohort. NeuroImage: Clinical, 2021, 30, 102646.	2.7	28
46	Disease-related cortical thinning in presymptomatic granulin mutation carriers. NeuroImage: Clinical, 2021, 29, 102540.	2.7	8
47	Matching Clinical Diagnosis and Amyloid Biomarkers in Alzheimerâ€™s Disease and Frontotemporal Dementia. Journal of Personalized Medicine, 2021, 11, 47.	2.5	9
48	Leukocyte-derived ratios are associated with late-life any type dementia: a cross-sectional analysis of the Mugello study. GeroScience, 2021, 43, 2785-2793.	4.6	6
49	Cerebral amyloid load determination in a clinical setting: interpretation of amyloid biomarker discordances aided by tau and neurodegeneration measurements. Neurological Sciences, 2021, , 1.	1.9	0
50	A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study. Molecular Neurodegeneration, 2021, 16, 79.	10.8	9
51	The implication of BDNF Val66Met polymorphism in progression from subjective cognitive decline to mild cognitive impairment and Alzheimerâ€™s disease: a 9-year follow-up study. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 471-482.	3.2	25
52	Role for ATXN1, ATXN2, and HTT intermediate repeats in frontotemporal dementia and Alzheimer's disease. Neurobiology of Aging, 2020, 87, 139.e1-139.e7.	3.1	35
53	Anti-MAG IgM: differences in antibody tests and correlation with clinical findings. Neurological Sciences, 2020, 41, 365-372.	1.9	9
54	Cerebrospinal fluid biomarkers for dementia: A case of post-lumbar puncture epidural hematoma. Clinical Neurology and Neurosurgery, 2020, 190, 105638.	1.4	0

#	Article	IF	Citations
55	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurology, The, 2020, 19, 145-156.	10.2	175
56	A case of limbic encephalitis evolving into a frontotemporal dementiaâ€like picture. Psychogeriatrics, 2020, 20, 355-357.	1.2	0
57	Linguistic profiles, brain metabolic patterns and rates of amyloid-Î² biomarker positivity in patients with mixed primary progressive aphasia. Neurobiology of Aging, 2020, 96, 155-164.	3.1	9
58	Neural correlates of naming errors across different neurodegenerative diseases. Neurology, 2020, 95, e2816-e2830.	1.1	19
59	Early symptoms in symptomatic and preclinical genetic frontotemporal lobar degeneration. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 975-984.	1.9	25
60	Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis. Scientific Reports, 2020, 10, 12184.	3.3	4
61	Challenges in Alzheimerâ€™s Disease Diagnostic Work-Up: Amyloid Biomarker Incongruences. Journal of Alzheimer's Disease, 2020, 77, 203-217.	2.6	3
62	C9orf72, age at onset, and ancestry help discriminate behavioral from language variants in FTLD cohorts. Neurology, 2020, 95, e3288-e3302.	1.1	7
63	Analysis of brain atrophy and local gene expression in genetic frontotemporal dementia. Brain Communications, 2020, 2, .	3.3	20
64	Influence of ApoE Genotype and Clock T3111C Interaction with Cardiovascular Risk Factors on the Progression to Alzheimerâ€™s Disease in Subjective Cognitive Decline and Mild Cognitive Impairment Patients. Journal of Personalized Medicine, 2020, 10, 45.	2.5	15
65	SIRT1 accelerates the progression of activity-based anorexia. Nature Communications, 2020, 11, 2814.	12.8	16
66	Early functional MRI changes in a prodromal semantic variant of primary progressive aphasia: a longitudinal case report. Journal of Neurology, 2020, 267, 3100-3104.	3.6	4
67	Human iPSC-Derived Hippocampal Spheroids: An Innovative Tool for Stratifying Alzheimer Disease Patient-Specific Cellular Phenotypes and Developing Therapies. Stem Cell Reports, 2020, 15, 256-273.	4.8	49
68	Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 263-270.	1.9	106
69	Faster Cortical Thinning and Surface Area Loss in Presymptomatic and Symptomatic C9orf72 Repeat Expansion Adult Carriers. Annals of Neurology, 2020, 88, 113-122.	5.3	19
70	Kitten Scanner reduces the use of sedation in pediatric MRI. Journal of Child Health Care, 2019, 23, 256-265.	1.4	14
71	Genome-wide association study identifies eight risk loci and implicates metabo-psychiatric origins for anorexia nervosa. Nature Genetics, 2019, 51, 1207-1214.	21.4	641
72	Raman profiling of circulating extracellular vesicles for the stratification of Parkinsonâ€™s patients. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 22, 102097.	3.3	35

#	Article	IF	Citations
73	High Frequency of Crossed Aphasia in Dextral in an Italian Cohort of Patients with Logopenic Primary Progressive Aphasia. Journal of Alzheimer's Disease, 2019, 72, 1089-1096.	2.6	2
74	Clinical and neuroimaging profiles to identify C9orf72 â€FTD patients and serum Neurofilament to monitor the progression and the severity of the disease. Neurology and Clinical Neuroscience, 2019, 7, 326-333.	0.4	1
75	Transethnic meta-analysis of rare coding variants in PLCG2, ABI3, and TREM2 supports their general contribution to Alzheimerâ€™s disease. Translational Psychiatry, 2019, 9, 55.	4.8	32
76	The inner fluctuations of the brain in presymptomatic Frontotemporal Dementia: The chronnectome fingerprint. NeuroImage, 2019, 189, 645-654.	4.2	33
77	Education modulates brain maintenance in presymptomatic frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1124-1130.	1.9	23
78	Dyskinesia-Hyperpyrexia Syndrome in Parkinson's disease with Deep Brain Stimulation and high-dose levodopa/carbidopa and entacapone. Parkinsonism and Related Disorders, 2019, 64, 352-353.	2.2	9
79	Associations Between Attention-Deficit/Hyperactivity Disorder and Various Eating Disorders: A Swedish Nationwide Population Study Using Multiple Genetically Informative Approaches. Biological Psychiatry, 2019, 86, 577-586.	1.3	43
80	Cerebral perfusion changes in presymptomatic genetic frontotemporal dementia: a GENFI study. Brain, 2019, 142, 1108-1120.	7.6	41
81	Acute Symptomatic Sinus Bradycardia in High-Dose Methylprednisolone Therapy in a Woman With Inflammatory Myelitis: A Case Report and Review of the Literature. Clinical Medicine Insights: Case Reports, 2019, 12, 117954761983102.	0.7	9
82	Crossed aphasia confirmed by fMRI in a case with nonfluent variant of primary progressive aphasia carrying a GRN mutation. Journal of Neurology, 2019, 266, 1274-1279.	3.6	3
83	KIBRA T allele influences memory performance and progression of cognitive decline: a 7-year follow-up study in subjective cognitive decline and mild cognitive impairment. Neurological Sciences, 2019, 40, 1559-1566.	1.9	10
84	Primary Progressive Aphasia. Alzheimer Disease and Associated Disorders, 2019, 33, 42-46.	1.3	12
85	Genetic meta-analysis of diagnosed Alzheimerâ€™s disease identifies new risk loci and implicates AÎ², tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	21.4	1,962
86	Ventricular volume expansion in presymptomatic genetic frontotemporal dementia. Neurology, 2019, 93, e1699-e1706.	1.1	19
87	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. NeuroImage: Clinical, 2019, 24, 102077.	2.7	27
88	Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. Lancet Neurology, The, 2019, 18, 165-176.	10.2	82
89	Spatiotemporal analysis for detection of pre-symptomatic shape changes in neurodegenerative diseases: Initial application to the GENFI cohort. NeuroImage, 2019, 188, 282-290.	4.2	16
90	The dual role of cognitive reserve in subjective cognitive decline and mild cognitive impairment: a 7-year follow-up study. Journal of Neurology, 2019, 266, 487-497.	3.6	51

#	Article	IF	Citations
91	Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia. Neurobiology of Aging, 2019, 77, 169-177.	3.1	47
92	Connected Speech Deficit as an Early Hallmark of CSF-defined Alzheimerâ€™s Disease and Correlation with Cerebral Hypoperfusion Pattern. Current Alzheimer Research, 2019, 16, 483-494.	1.4	14
93	Intravenous versus subcutaneous immunoglobulin â€“ Authors' reply. Lancet Neurology, The, 2018, 17, 393-394.	10.2	0
94	Novel GRN Mutations in Alzheimerâ€™s Disease and Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2018, 62, 1683-1689.	2.6	12
95	Biomarkers study in atypical dementia: proof of a diagnostic work-up. Neurological Sciences, 2018, 39, 1203-1210.	1.9	3
96	Improvement on the Coma Recovery Scaleâ€“Revised During the First Four Weeks of Hospital Stay Predicts Outcome at Discharge in Intensive Rehabilitation After Severe Brain Injury. Archives of Physical Medicine and Rehabilitation, 2018, 99, 914-919.	0.9	31
97	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	10.2	97
98	Rare Dementias. , 2018, , 313-336.		0
99	Rare nonsynonymous variants in SORT1 are associated with increased risk for frontotemporal dementia. Neurobiology of Aging, 2018, 66, 181.e3-181.e10.	3.1	19
100	Comparison of arterial spin labeling registration strategies in the multiâ€center GENetic frontotemporal dementia initiative (GENFI). Journal of Magnetic Resonance Imaging, 2018, 47, 131-140.	3.4	41
101	Patterns of gray matter atrophy in genetic frontotemporal dementia: results from the GENFI study. Neurobiology of Aging, 2018, 62, 191-196.	3.1	151
102	The diagnosis of dementias: a practical tool not to miss rare causes. Neurological Sciences, 2018, 39, 615-627.	1.9	14
103	Genetic Heterogeneity of Alzheimerâ€™s Disease: Embracing Research Partnerships. Journal of Alzheimer's Disease, 2018, 62, 903-911.	2.6	10
104	Progranulin plasma levels predict the presence of GRN mutations in asymptomatic subjects and do not correlate with brain atrophy: results from the GENFI study. Neurobiology of Aging, 2018, 62, 245.e9-245.e12.	3.1	40
105	Common and rare TBK1 variants in early-onset Alzheimer disease in a European cohort. Neurobiology of Aging, 2018, 62, 245.e1-245.e7.	3.1	16
106	Contribution of Bilingualism to Cognitive Reserve of an Italian Literature Professor at High Risk for Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 66, 1389-1395.	2.6	8
107	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. Brain, 2018, 141, 2895-2907.	7.6	39
108	Screening for Aphasia in NeuroDegeneration for the Diagnosis of Patients with Primary Progressive Aphasia: Clinical Validity and Psychometric Properties. Dementia and Geriatric Cognitive Disorders, 2018, 46, 243-252.	1.5	19

#	Article	IF	Citations
109	Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference. Nature Communications, 2018, 9, 4273.	12.8	263
110	Gender Differences in Neuropsychiatric Symptoms in Mild to Moderate Alzheimer's Disease Patients Undergoing Switch of Cholinesterase Inhibitors: APost HocAnalysis of the EVOLUTION Study. Journal of Women's Health, 2018, 27, 1368-1377.	3.3	32
111	From Subjective Cognitive Decline to Alzheimerâ€™s Disease: The Predictive Role of Neuropsychological Assessment, Personality Traits, and Cognitive Reserve. A 7-Year Follow-Up Study. Journal of Alzheimer's Disease, 2018, 63, 1523-1535.	2.6	68
112	Crossed aphasia in nonfluent variant of primary progressive aphasia carrying a GRN mutation. Journal of the Neurological Sciences, 2018, 392, 34-37.	0.6	7
113	Sporadic Fatal Insomnia in Europe: Phenotypic Features and Diagnostic Challenges. Annals of Neurology, 2018, 84, 347-360.	5.3	31
114	Distinct patterns of brain atrophy in Genetic Frontotemporal Dementia Initiative (GENFI) cohort revealed by visual rating scales. Alzheimer's Research and Therapy, 2018, 10, 46.	6.2	34
115	Presymptomatic white matter integrity loss in familial frontotemporal dementia in the <scp>GENFI</scp> cohort: A crossâ€sectional diffusion tensor imaging study. Annals of Clinical and Translational Neurology, 2018, 5, 1025-1036.	3.7	39
116	Distinct Neuroanatomical Correlates of Neuropsychiatric Symptoms in the Three Main Forms of Genetic Frontotemporal Dementia in the GENFI Cohort. Journal of Alzheimer's Disease, 2018, 65, 1-16.	2.6	28
117	No supportive evidence for TIA1 gene mutations in a European cohort of ALS-FTD spectrum patients. Neurobiology of Aging, 2018, 69, 293.e9-293.e11.	3.1	15
118	Impact of demography and population dynamics on the genetic architecture of human longevity. Aging, 2018, 10, 1947-1963.	3.1	16
119	Significant Locus and Metabolic Genetic Correlations Revealed in Genome-Wide Association Study of Anorexia Nervosa. American Journal of Psychiatry, 2017, 174, 850-858.	7.2	410
120	The novel PSEN1 M84V mutation associated to frontal dysexecutive syndrome, spastic paraparesis, and cerebellar atrophy in a dominant Alzheimer's disease family. Neurobiology of Aging, 2017, 56, 213.e7-213.e12.	3.1	19
121	Cognitive reserve and TMEM106B genotype modulate brain damage in presymptomatic frontotemporal dementia: a GENFI study. Brain, 2017, 140, 1784-1791.	7.6	55
122	Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimerâ€™s disease. Acta Neuropathologica, 2017, 134, 475-487.	7.7	53
123	White matter hyperintensities are seen only in GRN mutation carriers in the GENFI cohort. NeuroImage: Clinical, 2017, 15, 171-180.	2.7	63
124	TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Human Mutation, 2017, 38, 297-309.	2.5	87
125	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	21.4	783
126	Association of the New Variant Tyr424Asp at TBK1 Gene with Amyotrophic Lateral Sclerosis and Cognitive Decline. Journal of Alzheimer's Disease, 2017, 61, 41-46.	2.6	3

#	Article	IF	Citations
127	Bilateral isolated facial palsy with fast recovery in infectious mononucleosis. Neurological Sciences, 2017, 38, 369-371.	1.9	2
128	Low Florbetapir PET Uptake and Normal AÎ²1-42 Cerebrospinal Fluid in an APP Ala713Thr Mutation Carrier. Journal of Alzheimer's Disease, 2017, 57, 697-703.	2.6	5
129	Alzheimerâ€™s Disease Progression: Factors Influencing Cognitive Decline. Journal of Alzheimer's Disease, 2017, 61, 785-791.	2.6	37
130	Nonmotor Symptoms of Parkinsonâ€™s Disease. Parkinson's Disease, 2017, 2017, 1-2.	1.1	12
131	SAND: a Screening for Aphasia in NeuroDegeneration. Development and normative data. Neurological Sciences, 2017, 38, 1469-1483.	1.9	72
132	Fat mass and obesity-associated gene (FTO) is associated to eating disorders susceptibility and moderates the expression of psychopathological traits. PLoS ONE, 2017, 12, e0173560.	2.5	45
133	PRNP P39L Variant is a Rare Cause ofÂFrontotemporal Dementia in Italian Population. Journal of Alzheimer's Disease, 2016, 50, 353-357.	2.6	15
134	A systematic review of the quality of studies on dementia prevalence in Italy. BMC Health Services Research, 2016, 16, 615.	2.2	9
135	Genetic Counseling and Testing for Alzheimerâ€™s Disease and Frontotemporal Lobar Degeneration: An Italian Consensus Protocol. Journal of Alzheimer's Disease, 2016, 51, 277-291.	2.6	18
136	Shared genetic contribution to ischemic stroke and Alzheimer's disease. Annals of Neurology, 2016, 79, 739-747.	5.3	56
137	Analyses of the role of the glucocorticoid receptor gene polymorphism (rs41423247) as a potential moderator in the association between childhood overweight, psychopathology, and clinical outcomes in Eating Disorders patients: A 6 years follow up study. Psychiatry Research, 2016, 243, 156-160.	3.3	7
138	A systematic review of the quality of studies on dementia prevalence in Italy. BMC Health Services Research, 2016, 16, 507.	2.2	6
139	Cerebral metabolic rate of glucose quantification with the aortic image-derived input function and Patlak method. Nuclear Medicine Communications, 2016, 37, 849-859.	1.1	3
140	Rethinking on the concept of biomarkers in preclinical Alzheimerâ€™s disease. Neurological Sciences, 2016, 37, 663-672.	1.9	52
141	Novel presenilin 1 mutation (Ile408Thr) in an Italian family with late-onset Alzheimerâ€™s disease. Neuroscience Letters, 2016, 610, 150-153.	2.1	4
142	Rare Variants inPLD3Do Not Affect Risk for Early-Onset Alzheimer Disease in a European Consortium Cohort. Human Mutation, 2015, 36, 1226-1235.	2.5	23
143	Monomeric ÃŸ-amyloid interacts with type-1 insulin-like growth factor receptors to provide energy supply to neurons. Frontiers in Cellular Neuroscience, 2015, 9, 297.	3.7	44
144	Monitoring Neuro-Motor Recovery From Stroke With High-Resolution EEG, Robotics and Virtual Reality: A Proof of Concept. IEEE Transactions on Neural Systems and Rehabilitation Engineering, 2015, 23, 1106-1116.	4.9	46

#	Article	IF	Citations
145	Assessing neuro-motor recovery in a stroke survivor with high-resolution EEG, robotics and Virtual Reality. , 2015, 2015, 3925-8.		7
146	Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. Lancet Neurology, The, 2015, 14, 253-262.	10.2	432
147	The C9orf72 repeat expansion itself is methylated in ALS and FTLD patients. Acta Neuropathologica, 2015, 129, 715-727.	7.7	114
148	Sleep and Cognitive Decline: A Strong Bidirectional Relationship. It Is Time for Specific Recommendations on Routine Assessment and the Management of Sleep Disorders in Patients with Mild Cognitive Impairment and Dementia. European Neurology, 2015, 74, 43-48.	1.4	94
149	Genetic variability in SQSTM1 and risk of early-onset Alzheimer dementia: a European early-onset dementia consortium study. Neurobiology of Aging, 2015, 36, 2005.e15-2005.e22.	3.1	34
150	Csf p-tau₁₈₁/tau ratio as biomarker for TDP pathology in frontotemporal dementia. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 86-91.	1.7	65
151	Reliability of administrative data for the identification of Parkinsonâ€™s disease cohorts. Neurological Sciences, 2015, 36, 783-786.	1.9	23
152	Recommendations from the Italian Interdisciplinary Working Group (AIMN, AIP, SINDEM) for the utilization of amyloid imaging in clinical practice. Neurological Sciences, 2015, 36, 1075-1081.	1.9	35
153	Mutation analysis ofCHCHD10in different neurodegenerative diseases. Brain, 2015, 138, e380-e380.	7.6	86
154	A new social-family model for eating disorders: A European multicentre project using a caseâ€“control design. Appetite, 2015, 95, 544-553.	3.7	14
155	Convergent genetic and expression data implicate immunity in Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 658-671.	0.8	173
156	Mutation analysis of patients with neurodegenerative disorders using NeuroX array. Neurobiology of Aging, 2015, 36, 545.e9-545.e14.	3.1	36
157	Hypermethylation of the CpG-island near the C9orf72 G4C2-repeat expansion in FTLD patients. Human Molecular Genetics, 2014, 23, 5630-5637.	2.9	74
158	A Pilot Study Evaluating the Contribution ofSLC19A1(RFC-1) 80G>A Polymorphism to Alzheimerâ€™s Disease in Italian Caucasians. BioMed Research International, 2014, 2014, 1-6.	1.9	1
159	A psychosocial risk factor model for female eating disorders: a European multicentre project. Journal of Eating Disorders, 2014, 2, .	2.7	0
160	Advances in imagingâ€“genetic relationships for Alzheimerâ€™s disease: clinical implications. Neurodegenerative Disease Management, 2014, 4, 73-81.	2.2	5
161	Imaging and Cognitive Reserve Studies Predict Dementia in Presymptomatic Alzheimer's Disease Subjects. Neurodegenerative Diseases, 2014, 13, 157-159.	1.4	18
162	A genome-wide association meta-analysis identifies a novel locus at 17q11.2 associated with sporadic amyotrophic lateral sclerosis. Human Molecular Genetics, 2014, 23, 2220-2231.	2.9	123

#	Article	IF	Citations
163	Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. Acta Neuropathologica, 2014, 128, 397-410.	7.7	93
164	Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurology, The, 2014, 13, 686-699.	10.2	302
165	Heterozygous TREM2 mutations in frontotemporal dementia. Neurobiology of Aging, 2014, 35, 934.e7-934.e10.	3.1	134
166	Epigenetic Modifications in Alzheimer's Disease: Cause or Effect?. Journal of Alzheimer's Disease, 2014, 43, 1169-1173.	2.6	27
167	Association of the Variant Cys139Arg at GRN Gene to the Clinical Spectrum of Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2014, 40, 679-685.	2.6	11
168	Uncommon Dementias. , 2014, , 193-214.		1
169	Cognitive and Affective Changes in Mild to Moderate Alzheimerâ€™s Disease Patients Undergoing Switch of Cholinesterase Inhibitors: A 6-Month Observational Study. PLoS ONE, 2014, 9, e89216.	2.5	20
170	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. PLoS ONE, 2014, 9, e94661.	2.5	155
171	FDG PET and the genetics of dementia. Clinical and Translational Imaging, 2013, 1, 235-246.	2.1	2
172	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genetics, 2013, 45, 1452-1458.	21.4	3,741
173	How can elderly apolipoprotein E Îµ4 carriers remain free from dementia?. Neurobiology of Aging, 2013, 34, 13-21.	3.1	71
174	A Panâ€<scp>E</scp>uropean Study of theC9orf72Repeat Associated with<scp>FTLD</scp>: Geographic Prevalence, Genomic Instability, and Intermediate Repeats. Human Mutation, 2013, 34, 363-373.	2.5	247
175	Autosomal Dominant Frontotemporal Lobar Degeneration Due to the C9ORF72 Hexanucleotide Repeat Expansion: Late-Onset Psychotic Clinical Presentation. Biological Psychiatry, 2013, 74, 384-391.	1.3	105
176	Low social interactions in eating disorder patients in childhood and adulthood: A multi-centre European case control study. Journal of Health Psychology, 2013, 18, 26-37.	2.3	70
177	Yawning: A behavioural marker of sleepiness in de novo PD patients. Parkinsonism and Related Disorders, 2013, 19, 703-704.	2.2	1
178	Tomm40 polymorphisms in Italian Alzheimerâ€™s disease and frontotemporal dementia patients. Neurological Sciences, 2013, 34, 995-998.	1.9	28
179	The SIRT2 polymorphism rs10410544 and risk of Alzheimer's disease in two Caucasian caseâ€“control cohorts. Alzheimer's and Dementia, 2013, 9, 392-399.	0.8	40
180	Ataxia-telangiectasia mutated (ATM) genetic variant in Italian centenarians. Neurological Sciences, 2013, 34, 573-575.	1.9	17

#	Article	IF	Citations
181	Daytime course of sleepiness in de novo <scp>P</scp>arkinson's disease patients. Journal of Sleep Research, 2013, 22, 197-200.	3.2	11
182	Lipid Rafts Mediate Amyloid-Induced Calcium Dyshomeostasis and Oxidative Stress in Alzheimerâ€™s Disease. Current Alzheimer Research, 2013, 10, 143-153.	1.4	44
183	Genetics of familial and sporadic Alzheimer s disease. Frontiers in Bioscience - Elite, 2013, E5, 167-177.	1.8	166
184	Mutual Information Optimization for Mass Spectra Data Alignment. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2012, 9, 934-939.	3.0	7
185	DAPK1 is Associated with FTD and not with Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 32, 13-17.	2.6	4
186	Interaction of caudate dopamine depletion and brain metabolic changes with cognitive dysfunction in early Parkinson's disease. Neurobiology of Aging, 2012, 33, 206.e29-206.e39.	3.1	71
187	Mitochondria and Alzheimer's disease. Journal of the Neurological Sciences, 2012, 322, 31-34.	0.6	35
188	Suitability of neuropsychological tests in patients with vascular dementia (VaD). Journal of the Neurological Sciences, 2012, 322, 41-45.	0.6	9
189	Folate, Homocysteine, Vitamin B12, and Polymorphisms of Genes Participating in One-Carbon Metabolism in Late-Onset Alzheimer's Disease Patients and Healthy Controls. Antioxidants and Redox Signaling, 2012, 17, 195-204.	5.4	60
190	Fat Mass and Obesity-Associated Gene (<i>FTO</i>) in Eating Disorders: Evidence for Association of the rs9939609 Obesity Risk Allele with Bulimia nervosa and Anorexia nervosa. Obesity Facts, 2012, 5, 408-419.	3.4	46
191	Association between serotonin transporter gene polymorphism and eating disorders outcome: A 6â€year followâ€up study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2012, 159B, 491-500.	1.7	29
192	Novel S-acyl glutathione derivatives prevent amyloid oxidative stress and cholinergic dysfunction in Alzheimer disease models. Free Radical Biology and Medicine, 2012, 52, 1362-1371.	2.9	52
193	Progranulin Genetic Screening in Frontotemporal Lobar Degeneration Patients From Central Italy. Cellular and Molecular Neurobiology, 2012, 32, 13-16.	3.3	10
194	Position paper of the Italian Society for the study of Dementias (Sindem) on the proposal of a new Lexicon on Alzheimer disease. Neurological Sciences, 2012, 33, 201-208.	1.9	6
195	Implication of a Genetic Variant at PICALM in Alzheimer's Disease Patients and Centenarians. Journal of Alzheimer's Disease, 2011, 24, 409-413.	2.6	15
196	An APOE Haplotype Associated with Decreased Îµ4 Expression Increases the Risk of Late Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 24, 235-245.	2.6	58
197	Membrane cholesterol enrichment prevents AÎ²-induced oxidative stress in Alzheimer's fibroblasts. Neurobiology of Aging, 2011, 32, 210-222.	3.1	41
198	Evidence of the association of BIN1 and PICALM with the AD risk in contrasting European populations. Neurobiology of Aging, 2011, 32, 756.e11-756.e15.	3.1	82

#	Article	IF	Citations
199	Specific Silencing of L392VPSEN1Mutant Allele by RNA Interference. International Journal of Alzheimer's Disease, 2011, 2011, 1-14.	2.0	13
200	Association Study of Genetic Variants inCDKN2A/CDKN2BGenes/Loci with Late-Onset Alzheimer's Disease. International Journal of Alzheimer's Disease, 2011, 2011, 1-4.	2.0	5
201	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nature Genetics, 2011, 43, 429-435.	21.4	1,708
202	Factors of risk and maintenance for eating disorders: psychometric exploration of the crossâ€cultural questionnaire (CCQ) across five European countries. Clinical Psychology and Psychotherapy, 2011, 18, 535-552.	2.7	11
203	Implication of serotonin-transporter (5-HTT) gene polymorphism in subjective memory complaints and mild cognitive impairment (MCI). Archives of Gerontology and Geriatrics, 2011, 52, e71-e74.	3.0	17
204	Meta-analysis of the Association Between Variants in SORL1 and Alzheimer Disease. Archives of Neurology, 2011, 68, 99.	4.5	153
205	Glucocorticoid receptor gene polymorphisms in Italian patients with eating disorders and obesity. Psychiatric Genetics, 2010, 20, 282-288.	1.1	32
206	The CALHM1 P86L Polymorphism is a Genetic Modifier of Age at Onset in Alzheimer's Disease: a Meta-Analysis Study. Journal of Alzheimer's Disease, 2010, 22, 247-255.	2.6	54
207	Lack of Implication for CALHM1 P86L Common Variation in Italian Patients with Early and Late Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 20, 37-41.	2.6	18
208	Failure to Replicate an Association of rs5984894 SNP in the PCDH11X Gene in a Collection of 1,222 Alzheimer's Disease Affected Patients. Journal of Alzheimer's Disease, 2010, 21, 385-388.	2.6	11
209	Predictive potential of pre-operative functional neuroimaging in patients treated with subthalamic stimulation. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 12-22.	6.4	2
210	Brain metabolic correlates of dopaminergic degeneration in de novo idiopathic Parkinsonâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 537-544.	6.4	35
211	Lipid rafts are primary mediators of amyloid oxidative attack on plasma membrane. Journal of Molecular Medicine, 2010, 88, 597-608.	3.9	41
212	GAD antibodies associated neurological disorders: Incidence and phenotype distribution among neurological inflammatory diseases. Journal of Neuroimmunology, 2010, 227, 175-177.	2.3	10
213	Role of the neurotrophin network in eating disordersâ€™ subphenotypes: Body mass index and age at onset of the disease. Journal of Psychiatric Research, 2010, 44, 834-840.	3.1	10
214	Fibroblasts from PS1 Mutated Pre-Symptomatic Subjects and Alzheimer's Disease Patients Share a Unique Protein Levels Profile. Journal of Alzheimer's Disease, 2010, 21, 431-444.	2.6	8
215	Cognitive impairment predicts conversion to multiple sclerosis in clinically isolated syndromes. Multiple Sclerosis Journal, 2010, 16, 62-67.	3.0	144
216	Evidence for Sub-Haplogroup H5 of Mitochondrial DNA as a Risk Factor for Late Onset Alzheimer's Disease. PLoS ONE, 2010, 5, e12037.	2.5	117

#	Article	IF	Citations
217	Semantic dementia associated with mutation V363I in the tau gene. Journal of the Neurological Sciences, 2010, 296, 112-114.	0.6	39
218	Different implication of NEDD9 genetic variant in early and late-onset Alzheimer's disease. Neuroscience Letters, 2010, 477, 121-123.	2.1	8
219	Impact of cognitive impairment on coping strategies in multiple sclerosis. Clinical Neurology and Neurosurgery, 2010, 112, 127-130.	1.4	47
220	Complex repetitive behavior: Punding after bilateral subthalamic nucleus stimulation in Parkinson's disease. Parkinsonism and Related Disorders, 2010, 16, 376-380.	2.2	17
221	Effects of Donepezil, Galantamine and Rivastigmine in 938 Italian Patients with AlzheimerÊ¼s Disease. CNS Drugs, 2010, 24, 163-176.	5.9	44
222	Mutant Presenilin 1 Increases the Expression and Activity of BACE1. Journal of Biological Chemistry, 2009, 284, 9027-9038.	3.4	42
223	APOE-Îµ4 is not associated with cognitive impairment in relapsingâ€”remitting multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 1489-1494.	3.0	21
224	Implication of Sex and SORL1 Variants in Italian Patients With Alzheimer Disease. Archives of Neurology, 2009, 66, 1260-6.	4.5	45
225	Coping strategies, psychological variables and their relationship with quality of life in multiple sclerosis. Neurological Sciences, 2009, 30, 15-20.	1.9	110
226	Human longevity and 11p15.5: a study in 1321 centenarians. European Journal of Human Genetics, 2009, 17, 1515-1519.	2.8	60
227	On the multivariate nature of brain metabolic impairment in Alzheimer's disease. Neurobiology of Aging, 2009, 30, 186-197.	3.1	52
228	Associations of individual and family eating patterns during childhood and early adolescence: a multicentre European study of associated eating disorder factors. British Journal of Nutrition, 2009, 101, 909-918.	2.3	21
229	Implication of GAB2 Gene Polymorphism in Italian Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 16, 513-515.	2.6	22
230	Clinical correlation of the binding potential with 123I-FP-CIT in de novo idiopathic Parkinsonâ€™s disease patients. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 2220-2226.	6.4	8
231	Mutational screening analysis ofDHCR24/seladin-1 gene in Italian familial Alzheimer's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 117-119.	1.7	10
232	Protective effect of new S-acylglutathione derivatives against amyloid-induced oxidative stress. Free Radical Biology and Medicine, 2008, 44, 1624-1636.	2.9	33
233	Non-paraneoplastic limbic encephalitis associated with anti-glutamic acid decarboxylase antibodies. Journal of Neuroimmunology, 2008, 199, 155-159.	2.3	110
234	Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: An open-label comparative study of efficacy and safety. Journal of the Neurological Sciences, 2008, 266, 25-30.	0.6	23

#	Article	IF	Citations
235	KIBRA gene variants are associated with episodic memory performance in subjective memory complaints. Neuroscience Letters, 2008, 436, 145-147.	2.1	47
236	Lack of association between TNF-Î± polymorphisms and Alzheimerâ€™s disease in an Italian cohort. Neuroscience Letters, 2008, 446, 139-142.	2.1	20
237	Cathepsin D expression is decreased in Alzheimer's disease fibroblasts. Neurobiology of Aging, 2008, 29, 12-22.	3.1	61
238	Development of human striatal anlagen after transplantation in a patient with Huntington's disease. Experimental Neurology, 2008, 213, 241-244.	4.1	38
239	Present and lifetime comorbidity of tobacco, alcohol and drug use in eating disorders: A European multicenter study. Drug and Alcohol Dependence, 2008, 97, 169-179.	3.2	77
240	Interleukin-10 promoter polymorphisms influence susceptibility to ulcerative colitis in a gender-specific manner. Scandinavian Journal of Gastroenterology, 2008, 43, 712-718.	1.5	50
241	RNA interference in silencing of genes of Alzheimer's disease in cellular and rat brain models. Nucleic Acids Symposium Series, 2008, 52, 41-42.	0.3	12
242	Association of NTRK3 and its interaction with NGF suggest an altered cross-regulation of the neurotrophin signaling pathway in eating disorders. Human Molecular Genetics, 2008, 17, 1234-1244.	2.9	50
243	Multicenter Standardized ¹⁸F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementias. Journal of Nuclear Medicine, 2008, 49, 390-398.	5.0	637
244	SNPs in Neurotrophin System Genes and Alzheimer's Disease in an Italian Population. Journal of Alzheimer's Disease, 2008, 15, 61-70.	2.6	54
245	Fragile X Syndrome vs Fragile Xâ€“Associated Tremor/Ataxia Syndromeâ€”Reply. Archives of Neurology, 2007, 64, 289.	4.5	2
246	Association of Neocortical Volume Changes With Cognitive Deterioration in Relapsing-Remitting Multiple Sclerosis. Archives of Neurology, 2007, 64, 1157.	4.5	203
247	Pattern and Progression of Cognitive Decline in Alzheimerâ€™s Disease: Role of Premorbid Intelligence and ApoE Genotype. Dementia and Geriatric Cognitive Disorders, 2007, 24, 483-491.	1.5	32
248	Dramatic Reduction of Microemboli after Heparin Infusion in Progressing Stroke due to Aortic Arch Atheroma. European Neurology, 2007, 57, 172-175.	1.4	0
249	Increased susceptibility to amyloid toxicity in familial Alzheimer's fibroblasts. Neurobiology of Aging, 2007, 28, 863-876.	3.1	47
250	Association studies between the plasmin genes and late-onset Alzheimer's disease. Neurobiology of Aging, 2007, 28, 1041-1043.	3.1	12
251	Association of IL10 promoter polymorphism in Italian Alzheimer's disease. Neuroscience Letters, 2007, 418, 262-265.	2.1	39
252	Differences in Extracellular Matrix Production and Basic Fibroblast Growth Factor Response in Skin Fibroblasts from Sporadic and Familial Alzheimerâ€™s Disease. Molecular Medicine, 2007, 13, 542-550.	4.4	31

#	Article	IF	Citations
253	Angiotensin converting enzyme insertion/deletion polymorphism in sporadic and familial Alzheimer's disease and longevity. Archives of Gerontology and Geriatrics, 2007, 45, 201-206.	3.0	25
254	The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nature Genetics, 2007, 39, 168-177.	21.4	1,045
255	Fine specificity of antibodies against phospholipids and beta-2-glycoprotein I in monoclonal gammopathy associated neuropathies. Journal of Neuroimmunology, 2007, 182, 219-225.	2.3	4
256	Are there adaptive changes in the human brain of patients with Parkinsonâ€™s disease treated with long-term deep brain stimulation of the subthalamic nucleus? A 4-year follow-up study with regional cerebral blood flow SPECT. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 1646-1657.	6.4	11
257	Testing for Linkage and Association Across the Dihydrolipoyl Dehydrogenase Gene Region with Alzheimerâ€™s Disease in Three Sample Populations. Neurochemical Research, 2007, 32, 857-869.	3.3	15
258	No Association Between the LRRK2 G2019S Mutation and Alzheimerâ€™s disease in Italy. Cellular and Molecular Neurobiology, 2007, 27, 877-881.	3.3	13
259	Neocortical volume decrease in relapsingâ€“remitting multiple sclerosis with mild cognitive impairment. Journal of the Neurological Sciences, 2006, 245, 195-199.	0.6	30
260	Cystatin C and apoe polymorphisms in Italian Alzheimer's disease. Neuroscience Letters, 2006, 392, 110-113.	2.1	9
261	Association analysis of the paraoxonase-1 gene with Alzheimer's disease. Neuroscience Letters, 2006, 408, 199-202.	2.1	29
262	Immunoproteasome and LMP2 polymorphism in aged and Alzheimer's disease brains. Neurobiology of Aging, 2006, 27, 54-66.	3.1	184
263	Lack of association between the CYP46 gene polymorphism and Italian late-onset sporadic Alzheimer's disease. Neurobiology of Aging, 2006, 27, 773.e1-773.e3.	3.1	23
264	Fragile X Premutation With Atypical Symptoms at Onset. Archives of Neurology, 2006, 63, 1135.	4.5	24
265	Caseâ€“control and combined family trios analysis of three polymorphisms in the ghrelin gene in European patients with anorexia and bulimia nervosa. Psychiatric Genetics, 2006, 16, 51-52.	1.1	40
266	Benign multiple sclerosis. Journal of Neurology, 2006, 253, 1054-1059.	3.6	147
267	Presenilin mutations linked to familial Alzheimer's disease reduce endoplasmic reticulum and Golgi apparatus calcium levels. Cell Calcium, 2006, 39, 539-550.	2.4	136
268	Brain damage as detected by magnetization transfer imaging is less pronounced in benign than in early relapsing multiple sclerosis. Brain, 2006, 129, 2008-2016.	7.6	75
269	Orbitofrontal Dysfunction Related to Both Apathy and Disinhibition in Frontotemporal Dementia. Dementia and Geriatric Cognitive Disorders, 2006, 21, 373-379.	1.5	172
270	Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. Journal of Nuclear Medicine, 2006, 47, 1778-86.	5.0	195

#	Article	IF	Citations
271	Insulin Degrading Enzyme and Alpha-3 Catenin Polymorphisms in Italian Patients with Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2005, 19, 246-247.	1.3	16
272	Association of BDNF with restricting anorexia nervosa and minimum body mass index: a family-based association study of eight European populations. European Journal of Human Genetics, 2005, 13, 428-434.	2.8	131
273	Cholesteryl ester transfer protein (CETP) I405V polymorphism and longevity in Italian centenarians. Mechanisms of Ageing and Development, 2005, 126, 826-828.	4.6	57
274	Clinical and genetic study of a largeSPG4 Italian family. Movement Disorders, 2005, 20, 1055-1059.	3.9	33
275	The urokinase-plasminogen activator (PLAU) gene is not associated with late onset Alzheimer?s disease. Neurogenetics, 2005, 6, 53-54.	1.4	13
276	Toward the Validation of Functional Neuroimaging as a Potential Biomarker for Alzheimer?s Disease: Implications for Drug Development. Molecular Imaging and Biology, 2005, 7, 59-68.	2.6	17
277	Heterogeneity of Brain Glucose Metabolism in Mild Cognitive Impairment and Clinical Progression to Alzheimer Disease. Archives of Neurology, 2005, 62, 1728.	4.5	269
278	Regional cerebral metabolism in early Alzheimerâ€™s disease with clinically significant apathy or depression. Biological Psychiatry, 2005, 57, 412-421.	1.3	168
279	Brain networks underlying the clinical effects of long-term subthalamic stimulation for Parkinson's disease: a 4-year follow-up study with rCBF SPECT. Journal of Nuclear Medicine, 2005, 46, 1444-54.	5.0	36
280	Association of BDNF with anorexia, bulimia and age of onset of weight loss in six European populations. Human Molecular Genetics, 2004, 13, 1205-1212.	2.9	193
281	Neuropathological and Clinical Phenotype of an Italian Alzheimer Family with M239V Mutation of Presenilin 2 Gene. Journal of Neuropathology and Experimental Neurology, 2004, 63, 199-209.	1.7	39
282	Age and ApoE genotype interaction in Alzheimer's disease: an FDG-PET study. Psychiatry Research - Neuroimaging, 2004, 130, 141-151.	1.8	39
283	Brainâ€derived neurotrophic factor genetic variants are not susceptibility factors to Alzheimer's disease in Italy. Annals of Neurology, 2004, 55, 447-448.	5.3	41
284	Fibroblasts from FAD-linked presenilin 1 mutations display a normal unfolded protein response but overproduce AÎ²42 in response to tunicamycin. Neurobiology of Disease, 2004, 15, 380-386.	4.4	17
285	Psychopathological traits and 5-HT2A receptor promoter polymorphism (â^'1438 G/A) in patients suffering from Anorexia Nervosa and Bulimia Nervosa. Neuroscience Letters, 2004, 365, 92-96.	2.1	33
286	Brain-derived neurotrophic factor, apolipoprotein E genetic variants and cognitive performance in Alzheimerâ€™s disease. Neuroscience Letters, 2004, 367, 379-383.	2.1	50
287	Influence of Apolipoprotein E Ïµ4 Genotype on Brain Tissue Integrity in Relapsing-Remitting Multiple Sclerosis. Archives of Neurology, 2004, 61, 536.	4.5	45
288	Functional interactions of the entorhinal cortex: an 18F-FDG PET study on normal aging and Alzheimer's disease. Journal of Nuclear Medicine, 2004, 45, 382-92.	5.0	58

#	Article	IF	Citations
289	Absence of association between Alzheimer disease and the regulatory region polymorphism of the PS2 gene in an Italian population. Neuroscience Letters, 2003, 343, 210-212.	2.1	11
290	Up-regulation of Glycohydrolases in Alzheimer's Disease Fibroblasts Correlates with Ras Activation. Journal of Biological Chemistry, 2003, 278, 38453-38460.	3.4	41
291	Identification of New Presenilin Gene Mutations in Early-Onset Familial Alzheimer Disease. Archives of Neurology, 2003, 60, 1541.	4.5	45
292	A Family With Spinocerebellar Ataxia Type 8 Expansion and Vitamin E Deficiency Ataxia. Archives of Neurology, 2002, 59, 1952.	4.5	20
293	Neutrophils CD11b and fibroblasts PGE2 are elevated in Alzheimerâ€™s disease. Neurobiology of Aging, 2002, 23, 523-530.	3.1	53
294	5-HT2A receptor gene polymorphism and eating disorders. Neuroscience Letters, 2002, 323, 105-108.	2.1	70
295	Association study of the 5-hydroxytryptamine6 receptor gene in Alzheimer's disease. Neuroscience Letters, 2002, 325, 13-16.	2.1	24
296	Cathepsin D polymorphism in Italian sporadic and familial Alzheimer's disease. Neuroscience Letters, 2002, 328, 273-276.	2.1	25
297	Protein tyrosine phosphatase receptor-type C exon 4 gene mutation distribution in an Italian multiple sclerosis population. Neuroscience Letters, 2002, 328, 325-327.	2.1	33
298	Oxidative stress and reduced antioxidant defenses in peripheral cells from familial Alzheimerâ€™s patients. Free Radical Biology and Medicine, 2002, 33, 1372-1379.	2.9	139
299	Lack of association between NOS3 polymorphism and Italian sporadic and familial Alzheimer's disease. Journal of Neurology, 2002, 249, 110-111.	3.6	18
300	Association between 5-HT2A receptor polymorphism and psychotic symptoms in Alzheimerâ€™s disease. Biological Psychiatry, 2001, 50, 472-475.	1.3	62
301	Î±2-Macroglobulin polymorphisms in Italian sporadic and familial Alzheimer's disease. Neuroscience Letters, 2001, 299, 9-12.	2.1	19
302	The C677T methylenetetrahydrofolate reductase mutation is not associated with Alzheimer's disease. Neuroscience Letters, 2001, 315, 103-105.	2.1	47
303	Clinical and genetic analysis of an Italian family with Machado-Joseph disease. Journal of Neurology, 2001, 248, 717-719.	3.6	2
304	Mitochondrial DNA haplogroups and APOE4 allele are non-independent variables in sporadic Alzheimer's disease. Human Genetics, 2001, 108, 194-198.	3.8	154
305	Genetic risk factors in familial Alzheimer's disease. Mechanisms of Ageing and Development, 2001, 122, 1951-1960.	4.6	27
306	Cognitive Dysfunction in Early-Onset Multiple Sclerosis. Archives of Neurology, 2001, 58, 1602.	4.5	586

#	Article	IF	Citations
307	Double-Blind, Crossover, Placebo-Controlled Clinical Trial with L-Acetylcarnitine in Patients with Degenerative Cerebellar Ataxia. Clinical Neuropharmacology, 2000, 23, 114-118.	0.7	28
308	Association of early-onset Alzheimer's disease with an interleukin-1? gene polymorphism. Annals of Neurology, 2000, 47, 361-365.	5.3	358
309	Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and Î²APP processing. Nature, 2000, 407, 48-54.	27.8	895
310	Association Between Angiotensin-Converting Enzyme and Alzheimer Disease. Archives of Neurology, 2000, 57, 210.	4.5	96
311	Phospholipid composition and levels are not altered in fibroblasts bearing presenilin-1 mutations. Brain Research Bulletin, 2000, 52, 207-212.	3.0	3
312	Absence of linkage between familial amyotrophic lateral sclerosis and copper chaperone for the superoxide dismutase gene locus in two Italian pedigrees. Neuroscience Letters, 2000, 285, 83-86.	2.1	5
313	Lack of SOD1 gene mutations and activity alterations in two Italian families with amyotrophic lateral sclerosis. Neuroscience Letters, 2000, 289, 157-160.	2.1	2
314	Association of apolipoprotein E polymorphism to clinical heterogeneity of multiple sclerosis. Neuroscience Letters, 2000, 296, 174-176.	2.1	37
315	Oxidative Stress and a Key Metabolic Enzyme in Alzheimer Brains, Cultured Cells, and an Animal Model of Chronic Oxidative Deficits. Annals of the New York Academy of Sciences, 1999, 893, 79-94.	3.8	82
316	An Î±-2-macroglobulin insertion-deletion polymorphism in Alzheimer disease. Nature Genetics, 1999, 22, 19-21.	21.4	115
317	HLA A2 allele is associated with age at onset of Alzheimer's disease. Annals of Neurology, 1999, 45, 397-400.	5.3	29
318	p53 Codon 72 Polymorphism and Longevity: Additional Data on Centenarians from Continental Italy and Sardinia. American Journal of Human Genetics, 1999, 65, 1782-1785.	6.2	53
319	Gluthatione level is altered in lymphoblasts from patients with familial Alzheimer's disease. Neuroscience Letters, 1999, 275, 152-154.	2.1	107
320	5-HT2A receptor gene polymorphisms in anorexia nervosa and bulimia nervosa. Neuroscience Letters, 1999, 277, 134-136.	2.1	94
321	Association of the Estrogen Receptor Î± Gene Polymorphisms with Sporadic Alzheimer's Disease. Biochemical and Biophysical Research Communications, 1999, 265, 335-338.	2.1	122
322	Association between bleomycin hydrolase and Alzheimer's disease in caucasians. Annals of Neurology, 1998, 44, 808-811.	5.3	48
323	5-HT2A promoter polymorphism in anorexia nervosa. Lancet, The, 1998, 351, 1785.	13.7	84
324	Implication of Î±1-antichymotrypsin polymorphism in familial Alzheimer's disease. Neuroscience Letters, 1998, 244, 85-88.	2.1	17

#	Article	IF	Citations
325	No implication of apolipoprotein E polymorphism in Italian schizophrenic patients. Neuroscience Letters, 1998, 244, 118-120.	2.1	19
326	Growth Properties and Growth Factor Responsiveness in Skin Fibroblasts from Centenarians. Biochemical and Biophysical Research Communications, 1998, 244, 912-916.	2.1	35
327	Alpha1 antichymotrypsin signal peptide polymorphism in sporadic Creutzfeldtâ€“Jakob disease. Neuroscience Letters, 1997, 227, 140-142.	2.1	9
328	Analysis of apolipoprotein E, Î±1-antichymotrypsin and presenilin-1 genes polymorphisms in dementia caused by normal pressure hydrocephalus in man. Neuroscience Letters, 1997, 229, 177-180.	2.1	18
329	Presenilin-1 gene intronic polymorphism in sporadic and familial Azheimer's disease. Neuroscience Letters, 1997, 222, 132-134.	2.1	27
330	Inherent Abnormalities in Oxidative Metabolism in Alzheimer's Disease: Interaction with Vascular Abnormalities. Annals of the New York Academy of Sciences, 1997, 826, 382-385.	3.8	25
331	The effect of tetraethylammonium on intracellular calcium concentration in Alzheimer's disease fibroblasts with APP, S182 and E5-1 missense mutations. Neuroscience Letters, 1996, 208, 216-218.	2.1	6
332	Alteration of acylphosphatase levels in familial Alzheimer's disease fibroblasts with presenilin gene mutations. Neuroscience Letters, 1996, 210, 153-156.	2.1	17
333	C-Fos/C-Jun Expression and AP-1 Activation in Skin Fibroblasts from Centenarians. Biochemical and Biophysical Research Communications, 1996, 226, 517-523.	2.1	31
334	Apolipoprotein E and ?1-antichymotrypsin polymorphism in Alzheimer's disease. Annals of Neurology, 1996, 40, 678-680.	5.3	36
335	Alterations in Metabolic Properties in Fibroblasts in Alzheimer Disease. Alzheimer Disease and Associated Disorders, 1995, 9, 73-77.	1.3	19
336	Epistatic effect of APP717 mutation and apolipoprotein E genotype in familial Alzheimer's disease. Annals of Neurology, 1995, 38, 124-127.	5.3	110
337	ApoE as a prognostic factor for postâ€“traumatic coma. Nature Medicine, 1995, 1, 852-852.	30.7	145
338	Apolipoprotein E in sporadic and familial Creutzfeldt-Jakob disease. Neuroscience Letters, 1995, 199, 95-98.	2.1	39
339	Misserise mutation of S182 gene in Italian families with early-onset Alzheimer's disease. Lancet, The, 1995, 346, 439-440.	13.7	69
340	ApoE genotype and familial Alzheimer's disease: a possible influence on age of onset in APP717 Val â†' Ile mutated families. Neuroscience Letters, 1995, 183, 1-3.	2.1	63
341	Freed-amino acids in human cerebrospinal fluid of alzheimer disease, multiple sclerosis, and healthy control subjects. Molecular and Chemical Neuropathology, 1994, 23, 115-124.	1.0	59
342	Molecular genetics of Alzheimer's disease in Italian families. Neurochemistry International, 1994, 25, 81-84.	3.8	1

#	Article	IF	Citations
343	ApoE allele frequencies in Italian sporadic and familial Alzheimer's disease. Neuroscience Letters, 1994, 177, 100-102.	2.1	134
344	APP717 and Alzheimer's disease in Italy. Nature Genetics, 1993, 4, 10-10.	21.4	37
345	Occurrence of transketolase abnormalities in extracts of foreskin fibroblasts from patients with Alzheimer's disease. Biochemical and Biophysical Research Communications, 1990, 172, 396-401.	2.1	19
346	Intralaminar Distribution of Neurotransmitter-Related Enzymes in Cerebral Cortex of Alzheimerâ€™s Disease. Gerontology, 1987, 33, 197-202.	2.8	9
347	Energy metabolism in demented brain. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1986, 10, 591-597.	4.8	10
348	Abnormal platelet glutamate dehydrogenase activity and activation in dominant and nondominant olivopontocerebellar atrophy. Annals of Neurology, 1986, 19, 239-245.	5.3	29
349	Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain. Annals of Neurology, 1983, 13, 72-78.	5.3	350
350	Changes in high affinity choline uptake in rat cortex following lesions of the magnocellular forebrain nuclei. Brain Research, 1982, 233, 359-367.	2.2	99
351	Spectrophotometric measurement of pyruvate dehydrogenase complex activity in cultured human fibroblasts. Journal of Proteomics, 1981, 5, 169-176.	2.4	23